- Home
- CAPR vs LPAA Comparison
CAPR vs LPAA Comparison
Compare CAPR & LPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- LPAA
- Stock Information
- Founded
- CAPR 2005
- LPAA 2024
- Country
- CAPR United States
- LPAA United States
- Employees
- CAPR N/A
- LPAA N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- LPAA
- Sector
- CAPR Health Care
- LPAA
- Exchange
- CAPR Nasdaq
- LPAA Nasdaq
- Market Cap
- CAPR 324.6M
- LPAA 299.3M
- IPO Year
- CAPR N/A
- LPAA 2024
- Fundamental
- Price
- CAPR $6.28
- LPAA $10.48
- Analyst Decision
- CAPR Strong Buy
- LPAA
- Analyst Count
- CAPR 8
- LPAA 0
- Target Price
- CAPR $24.75
- LPAA N/A
- AVG Volume (30 Days)
- CAPR 1.4M
- LPAA 12.8K
- Earning Date
- CAPR 08-11-2025
- LPAA 01-01-0001
- Dividend Yield
- CAPR N/A
- LPAA N/A
- EPS Growth
- CAPR N/A
- LPAA N/A
- EPS
- CAPR N/A
- LPAA 0.35
- Revenue
- CAPR $13,392,150.00
- LPAA N/A
- Revenue This Year
- CAPR N/A
- LPAA N/A
- Revenue Next Year
- CAPR $6,061.53
- LPAA N/A
- P/E Ratio
- CAPR N/A
- LPAA $29.76
- Revenue Growth
- CAPR N/A
- LPAA N/A
- 52 Week Low
- CAPR $3.98
- LPAA $9.66
- 52 Week High
- CAPR $23.40
- LPAA $10.70
- Technical
- Relative Strength Index (RSI)
- CAPR 36.33
- LPAA 70.12
- Support Level
- CAPR $6.17
- LPAA $10.43
- Resistance Level
- CAPR $7.30
- LPAA $10.45
- Average True Range (ATR)
- CAPR 0.43
- LPAA 0.01
- MACD
- CAPR -0.11
- LPAA 0.00
- Stochastic Oscillator
- CAPR 4.53
- LPAA 100.00
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.